Atlas Venture Life Science Advisors, LLC Q3 2022 Filing
Filed November 9, 2022
Portfolio Value
$906.2B
Holdings
17
Report Date
Q3 2022
Filing Type
13F-HR
All Holdings (17 positions)
| Stock | Value |
|---|---|
THRDThird Harmonic Bio, Inc. | $206.9M |
DAWNDay One Biopharmaceuticals, Inc. | $163.6M |
KYMRKymera Therapeutics, Inc. | $149.7M |
DYNDyne Therapeutics, Inc. | $113.5M |
REPLReplimune Group, Inc. | $53.7M |
VIGLVigil Neuroscience, Inc. | $53.1M |
GBIOGBXGeneration Bio, Co. | $44.0M |
AVTEAerovate Therapeutics, Inc. | $38.6M |
AKROAkero Therapeutics, Inc. | $33.9M |
—Ikena Oncology, Inc. | $17.8M |
—Gemini Therapeutics, Inc. | $8.6M |
XLOXilio Therapeutics, Inc. | $8.0M |
—Magenta Therapeutics, Inc. | $4.9M |
—F-star Therapeutics, Inc. | $3.1M |
—AvroBio, Inc. | $2.9M |
SPROSpero Therapeutics, Inc. | $2.1M |
VRDNViridian Therapeutics, Inc. | $1.8M |